Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 272-281

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Inflammation; Insulin resistance; Pioglitazone; PPAR ; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ARYLDIALKYLPHOSPHATASE 1; BEZAFIBRATE; CREATININE; EXENDIN 4; FARGLITAZAR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SIBUTRAMINE; SITAGLIPTIN; TESAGLITAZAR; TROGLITAZONE; VILDAGLIPTIN;

ADIPOSE TISSUE; ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARCINOGENICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ECHOGRAPHY; EDEMA; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKELETAL MUSCLE; STROKE; WEIGHT GAIN;

EID: 84861744643     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020272     Document Type: Review

References (72)

1. Lee, C.H.; Olson, P.; Evans, R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 2003, 144, 2201-2207.
2. Marx, N.; Duez, H.; Fruchart, J.C.; Staels, B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res., 2004, 94, 1168-1178.
3. Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43, 527-550.
4. Brown, J.D.; Plutzky, J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation, 2007, 115, 518-533.
5. Shulman, A.I.; Mangelsdorf, D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med., 2005, 353, 604-615.
6. Fruchart, J.C.; Staels, B.; Duriez, P. The role of fibric acids in atherosclerosis. Curr. Atheroscler. Rep., 2001, 3, 83-92.
7. Giannini, S.; Serio, M.; Galli, A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J. Endocrinol. Invest., 2004, 27, 982-991.
8. Luquet, S.; Gaudel, C.; Holst, D.; Lopez-Soriano, J.; Jehl-Pietri, C.; Fredenrich, A.; Grimaldi, P.A. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta, 2005, 1740, 313-317.
9. Henke, B.R.; Blanchard, S.G.; Brackeen, M.F.; Brown, K.K.; Cobb, J.E.; Collins, J.L.; Harrington, W.W.; Hashim, M.A.; Hull-Ryde, E.A.; Kaldor, I.; Kliewer, S.A.; Lake, D.H.; Leesnitzer, L.M.; Lehmann, J.M.; Lenhard, J.M.; Orband-Miller, L.A.; Miller, J.F.; Mook, R.A.; Noble, S.A.; Oliver, W.; Parks, D.J.; Plunket, K.D.; Szewczyk, J.R.; Willson, T.M. N-(2-Benzoylphenyl)-Ltyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem., 1998, 41, 5020-5036.
10. Lohray, B.B.; Lohray, V.B.; Bajji, A.C.; Kalchar, S.; Poondra, R.R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R.K.; Misra, P.; Juluri, S.; Mamidi, N.V.S.R.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-) DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem., 2001, 44, 2675-2678.
11. Hegarty, B.D.; Furler, S.M.; Oakes, N.D.; Kraegen, E.W.; Cooney, G.J. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. Endocrinology, 2004, 145, 3158-3164.
12. Kendall, D.M.; Rubin, C.J.; Mohideen, P.; Ledeine, J.M.; Belder, R.; Gross, J.; Norwood, P.; O'Mahony, M.; Sall, K.; Sloan, G.; Roberts, A.; Fiedorek, F.T.; DeFronzo, R.A. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferatoractivated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A doubleblind, randomized, pioglitazone-comparative study. Diabetes Care, 2006, 29(5), 1016-1023.
13. Meade, T.; Zuhrie, R.; Cook, C.; Cooper, J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ, 2002, 325, 1139.
14. Greene, M.E.; Blumberg, B.; McBride, O.W.; Yi, H.F.; Kronquist, K.; Kwan, K.; Hsieh, L.; Greene, G.; Nimer, S.D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr., 1995, 4(4-5), 281-299.
15. Elbrecht, A.; Chen, Y.; Cullinan, C.A.; Hayes, N.; Leibowitz, M.; Moller, D.E.; Berger, J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun., 1996, 224(2), 431-437.
16. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58(4), 726-741.
17. Fajas, L.; Auboeuf, D.; Raspé, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M.R.; Staels, B.; Vidal, H.; Auwerx, J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 1997, 272(30), 18779-18789.
18. Jones, J.R.; Barrick, C.; Kim, K.A.; Lindner, J.; Blondeau, B.; Fujimoto, Y.; Shiota, M.; Kesterson, R.A.; Kahn, B.B.; Magnuson, M.A. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci., 2005, 102(17), 6207-6212.
19. Waki, H., Yamauchi, T.; Kadowaki, T. Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma. Nihon Rinsho, 2010, 68(2), 210-216.
20. Panigrahy, D.; Singer, S.; Shen, L.Q.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J.A.; Hlatky, L.; Hahnfeldt, P.; Folkman, J.; Kaipainen, A. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 2002, 110(7), 923-932.
21. Hamblin, M.; Chang, L.; Fan, Y.; Zhang, J.; Chen, Y.E. PPARs and the cardiovascular system. Antioxid. Redox Signal., 2009, 11(6), 1415-1452.
22. Khateeb, J.; Gantman, A.; Kreitenberg, A.J.; Aviram, M.; Fuhrman, B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis, 2010, 208(1), 119-125.
23. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. MMWR, 2004, 53(45), 1066-1068.
24. Barnett, A.H. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc. Health Risk Manag., 2009, 5, 141-151.
25. Bloomgarden, Z.T. The Avandia debate. Diabetes Care, 2007, 30, 2401-2408.
26. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356(24), 2457-2471.
27. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Hoogwerf, B.; Laakso, M.; Mohan, V.; Shaw, J.; Zinman, B.; Holman, R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006, 368, 1096-1105.
28. Kahn, S.E.; Haffner, S.M.; Heiase, M.A. and ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med., 2006, 355, 2427-2443.
29. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009, 373, 2125-2135.
30. Kaul, S.; Diamond, G.A. Rosiglitazone and cardiovascular risk. Curr. Atheroscler. Rep., 2008, 10(5), 398-404.
31. Graham, D.J.; Ouellet-Hellstrom, R.; MaCurdy, T.E.; Ali, F.; Sholley, C.; Worrall, C.; Kelman, J.A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, 304(4), 411-418.
32. Nissen, S.E.; Wolski, K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. N. Arch. Intern. Med., 2010; 170(14), 1191-1201.
33. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs, 2010, 70(15), 1945-1961.
34. Hundal, R.S.; Inzucchi, S.E. Metformin: new understandings, new uses. Drugs, 2003, 63, 1879-1894.
35. Derosa, G.; Mereu, R.; Salvadeo, S.A.; D'Angelo, A.; Ciccarelli, L.; Piccinni, M.N.; Ferrari, I.; Gravina, A.; Maffioli, P.; Cicero, A.F. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Intern. Med., 2009, 48(5), 265-271.
36. Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 2004, 64, 1339-1358.
37. Derosa, G.; Maffioli, P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol. Ther., 2010, 12(6), 491-501.
38. Krentz, A.J.; Bailey, C.J. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
39. Derosa, G.; Mereu, R.; D'Angelo, A.; Salvadeo, S.A.; Ferrari, I.; Fogari, E.; Gravina, A.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J. Clin. Pharm. Ther., 2010, 35(5), 565-579.
40. Derosa, G.; D'Angelo, A.; Salvadeo, S.A.; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed. Pharmacother., 2009, 63(10), 723-733.
41. Triplitt, C.L. New technologies and therapies in the management of diabetes. Am. J. Manag. Care, 2007, 13(2), 547-554.
42. Derosa, G.; Maffioli, P.; Ferrari, I.; Mereu, R.; Ragonesi, P.D.; Querci, F.; Franzetti, I.G.; Gadaleta, G.; Ciccarelli, L.; Piccinni, M.N.; D'Angelo, A.; Salvadeo, S.A. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm. Metab. Res., 2010, 42(9), 663-669.
43. Bolli, G.; Dotta, F.; Rochotte, E.; Cohen, S.E. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes. Metab., 2008, 10, 82-90.
44. Derosa, G.; Maffioli, P.; Salvadeo, S.A.; Ferrari, I.; Ragonesi, P.D.; Querci, F.; Franzetti, I.G.; Gadaleta, G.; Ciccarelli, L.; Piccinni, M.N.; D'Angelo, A.; Cicero, A.F. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism, 2010, 59(6), 887-895.
45. Derosa, G.; Maffioli, P.; Salvadeo, S.A.; Ferrari, I.; Gravina, A.; Mereu, R.; Palumbo, I.; D'Angelo, A.; Cicero, A.F. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism, 2009, 58(8), 1059-1066.
46. Proks, P.; Reimann, F.; Green, N.; Gribble, F.; Ashcroft, F. Sulfonylurea stimulation of insulin secretion. Diabetes, 2002, 51, S368-S376.
47. Einhorn, D.; Rendell, M.; Rosenzweig, J.; Egan, J.W.; Mathisen, A.L.; Schneider, R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther., 2000, 22, 1395-1409.
48. Derosa, G.; D'Angelo, A.; Ragonesi, P.D.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.A.; Montagna, L.; Gravina, A.; Ferrari, I.; Paniga, S.; Cicero, A.F. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern. Med. J., 2007, 37, 79-86.
49. Derosa, G.; D'Angelo, A.; Ragonesi, P.D.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.A.; Montagna, L.; Gravina, A.; Ferrari, I.; Paniga, S.; Cicero, A.F. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J. Clin. Pharm. Ther., 2006, 31, 375-383.
50. Matthews, D.R.; Charbonnel, B.H.; Hanefeld, M.; Brunetti, P.; Schernthaner, G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab. Res. Rev., 2005, 21, 167-174.
51. Haffner, S.M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339(4), 229-234.
52. Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Nesto, R.; Kupfer, S.; Perez, A.; Jure, H.; De Larochellière, R.; Staniloae, C.S.; Mavromatis, K.; Saw, J.; Hu, B.; Lincoff, A.M.; Tuzcu, E.M.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, 2008, 299(13), 1561-1573.
53. Mazzone, T.; Meyer, P.M.; Feinstein, S.B.; Davidson, M.H.; Kondos, G.T.; D'Agostino, R.B. Sr.; Perez, A.; Provost, J.C.; Haffner, S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006, 296(21), 2572-2581.
54. Hodis, H.N.; Mack, W.J.; LaBree, L.; Selzer, R.H.; Liu, C.R.; Liu, C.H.; Azen, S.P. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med., 1998, 128, 262-269.
55. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287(19), 2570-2582.
56. Fontbonne, A.; Charles, M.A.; Thibult, N.; Richard, J.L.; Claude, J.R.; Warnet, J.M.; Rosselin, G.E.; Eschwège, E. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia, 1991, 34(5), 356-361.
57. Derosa, G.; D'Angelo, A.; Salvadeo, S.A.; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc. Res., 2010, 79(2), 144-149.
58. Derosa, G.; D'Angelo, A.; Salvadeo, S.A.; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm. Metab. Res., 2010, 42(1), 8-13.
59. Peake, P.W.; Kriketos, A.D.; Campbell, L.V.; Charlesworth, J.A. Response of the alternative complement pathway to an oral fat load in fi rst-degree relatives of subjects with type II diabetes. Int. J. Obes., 2005, 29(4), 429-435.
60. Derosa, G.; Ferrari, I.; D'Angelo, A.; Salvadeo, S.A.; Fogari, E.; Gravina, A.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels, 2009, 24(3), 204-210.
61. Derosa, G.; Ferrari, I.; D'Angelo, A.; Salvadeo, S.A.; Fogari, E.; Gravina, A.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvasc. Res., 2010, 80(1), 110-115.
62. Derosa, G.; Cicero, A.F.G.; Fogari, E.; D'Angelo, A.; Bianchi, L.; Maffioli, P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm. Metab. Res., 2011, 43(7), 505-512.
63. Marx, N.; Sukhova, G.; Murphy, C.; Libby, P.; Plutzky, J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro. Am. J. Pathol., 1998, 153, 17-23.
64. Derosa, G.; Fogari, E.; Cicero, A.F.; D'Angelo, A.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.A.; Gravina, A.; Ferrari, I.; Fogari, R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens. Res., 2007, 30(5), 387-394.
65. Derosa, G.; Cicero, A.F.; D'angelo, A.; Gaddi, A.; Ragonesi, P.D.; Piccinni, M.N.; Salvadeo, S.; Ciccarelli, L.; Pricolo, F.; Ghelfi, M.; Ferrari, I.; Montagna, L.; Fogari, R. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens. Res., 2005, 28(11), 917-924.
66. DeFronzo, R.A.; Tripathy, D.; Schwenke, D.C.; Banerji, M.A.; Bray, G.A.; Buchanan, T.A.; Clement, S.C.; Henry, R.R.; Hodis, H.N.; Kitabchi, A.E.; Mack, W.J.; Mudaliar, S.; Ratner, R.E.; Williams, K.; Stentz, F.B.; Musi, N.; Reaven, P.D.; for the ACT NOW Study. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. N. Engl. J. Med., 2011, 364, 1104-1115.
67. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med., 2004, 351, 1106-1118.
68. Derosa, G.; Tinelli, C.; Maffioli, P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes. Metab., 2009, 11, 1091-1099.
69. Katoh, S.; Mori, Y.; Yokoyama, J. Effect of oral hypoglycaemic agents on fat distribution and glucose tolerance in non-insulindependent diabetes mellitus patients. J. Jpn. Diabetes Soc., 1998, 41, 289-293.
70. Diamant, M.; Heine, R. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, 63, 1373-1405.
71. Wiwanitkit, V. Glucosuria and albuminuria in diabetic nephropathy: a consideration at nanolevel. J. Diabetes Complications, 2007, 21(3), 164-165.
72. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefèbvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366(9493), 1279-1289.